Indirect comparison of bronchial thermoplasty versus omalizumab for uncontrolled severe asthma

References

• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2016 [cited 2016 Sept 19]. Available from: wwwginaasthma.org
   Google Scholar
• Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006;100(7):1139–1151.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360(10):973–984.
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014;(1):CD003559.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380(9842):651–659.
   PubMed Web of Science ®Google Scholar
• Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade LM, Shah PL, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010;181(2):116–124.
   PubMed Web of Science ®Google Scholar
• Eisner MD, Zazzali JL, Miller MK, Bradley MS, Schatz M. Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study. J Asthma 2012;49(6):642–648.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR, Shah PL, et al. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013;132(6):1295–1302.
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184–190.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34(4):632–638.
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18(2):254–261.
   PubMed Web of Science ®Google Scholar
• Chipps BE, Corren J, Israel E, Katial R, Lang DM, Panettieri RA et al. Asthma Yardstick -Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma. Ann Allergy Asthma Immunol 2017;118(2):113–142.
   PubMed Web of Science ®Google Scholar
• Australian Government Department of Health. The Pharmaceutical Benefits Advisory Committee Guidelines (Version 4.5). 2015 [cited 2016 Sept 19]. Available from: https://pbac.pbs.gov.au/information/printable-version-of-guidelines.html.
   Google Scholar
• Australian Governemnt Department of health. Technical Guidelines for preparing assessment reports for the Medical Services Advisory Committee - Medical Service Type: Therapeutic (Version 2.0). 2016 [cited 2016 Sept 19]. Available from: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/0BD63667C984FEEACA25801000123AD8/$File/TherapeuticTechnicalGuidelines-Final-March2016-Version2.0-accessible.pdf
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50(6):683–691.
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147(4):832–838.
   PubMed Web of Science ®Google Scholar
• Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma. 2011 [cited 2016 Sept 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT00567476
   Google Scholar
• Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011;66(5):671–678.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154(9):573–582.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309–316.
   PubMed Web of Science ®Google Scholar
• Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008;102(10):1371–1378.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA, Niven RM, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med 2007;176(12):1185–1191.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Thomson NC, Niven RM, Corris PA, Chung KF, Cox G, et al. Safety of bronchial thermoplasty in patients with severe refractory asthma. Ann Allergy Asthma Immunol 2013;111(5):402–407.
   PubMed Web of Science ®Google Scholar
• Bicknell S, Chaudhuri R, Lee N, Shepherd M, Spears M, Pitman N, et al. Effectiveness of bronchial thermoplasty in severe asthma in ‘real life’ patients compared with those recruited to clinical trials in the same centre. Ther Adv Respir Dis 2015;9(6):267–271.
   PubMed Web of Science ®Google Scholar
• Burn J, Sims A, Bousfield D, Patrick H, Welham S, Heaney L. P171 Efficacy and safety of bronchial thermoplasty in clinical practice: early results from a national registry. Thorax 2013;68(Suppl 3):A152–A153.
   Web of Science ®Google Scholar
• Burn J, Sims AJ, Keltie K, Patrick H, Welham S, Niven RM, et al. S12 Efficacy of bronchial thermoplasty in clinical practice using the British Thoracic Society UK Difficult Asthma Registry and Hospital Episode Statistics. Thorax 2015;70(Suppl 3):A11.
   Web of Science ®Google Scholar
• Chakir J, Haj-Salem I, Gras D, Joubert P, Beaudoin E-L, Biardel S, et al. Effects of bronchial thermoplasty on airway smooth muscle and collagen deposition in asthma. Ann ATS 2015;12(11):1612–1618.
   Google Scholar
• Fernandez-Bussy S, Labarca G, Caviedes I, Folch E, Majid A. Bronchial thermoplasty for severe asthma: Initial experience in Chile. Arch Bronconeumol 2016;52(1):52.
   PubMed Web of Science ®Google Scholar
• Riddell P, Lawrie I, Lane S, Egan J. Bronchial Thermoplasty For Severe Persistent Asthma, An Irish Experience. The Spy Who Loved Bronchoscopy: Advances in International Interventional Pulmonary Procedures. American Thoracic Society; 2014. p. A4409.
   Google Scholar
• Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60(3):302–308.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;101(7):1483–1492.
   PubMed Web of Science ®Google Scholar
• Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Respir Med 2009;103(8):1098–1113.
   PubMed Web of Science ®Google Scholar
• Sandstrom T. Omalizumab in the management of patients with allergic (IgE-mediated) asthma. J Asthma Allergy 2009;2:49–62.
   PubMedGoogle Scholar
• Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013;187(8):804–811.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14(4):417–428.
   PubMed Web of Science ®Google Scholar